Anzeige
Erschienen in:
13.10.2022 | Research
Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer
Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2022
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Although osimertinib has excellent intracranial activity in metastatic non-small cell lung cancer (NSCLC) with exon 19 deletion or L858R EGFR alterations, measures of local control of brain metastases are less well-reported. We describe lesion-level outcomes of brain metastases treated with osimertinib alone.
Methods
We retrospectively reviewed patients with EGFR-mutant NSCLC with untreated brain metastasis measuring ≥ 5 mm at the time of initiating osimertinib. Cumulative incidence of local recurrence in brain (LRiB) was calculated with death as a competing risk, and univariable and multivariable analyses were conducted to identify factors associated with LRiB.
Results
We included 284 brain metastases from 37 patients. Median follow-up was 20.1 months. On initial MRI after starting osimertinib, patient-level response was complete response (CR) in 11 (15%), partial response (PR) in 33 (45%), stable disease (SD) in 18 (25%) and progressive disease (PD) in 11 (15%). The 1-year cumulative incidence of LRiB was 14% (95% CI 9.9–17.9) and was significantly different in patients with a CR (0%), PR (4%), and SD (11%; p = 0.02). Uncontrolled primary tumor (adjusted hazard ratio [aHR] 3.78, 95% CI 1.87–7.66; p < 0.001), increasing number of prior systemic therapies (aHR 2.12, 95% CI 1.49–3.04; p < 0.001), and higher ECOG score (aHR 7.8, 95% CI 1.99–31.81; p = 0.003) were associated with LRiB.
Conclusions
Although 1-year cumulative incidence of LRiB is < 4% with a CR or PR, 1-year cumulative incidence of LRiB is over 10% for patients with less than a PR to osimertinib on initial MRI. These patients should be followed closely for need for additional treatment such as stereotactic radiosurgery.
